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ABSTRACT
Aminobisphosphonates (NBPs) are used widely against excessive bone resorption in osteoporosis and Paget’s disease as well as in
metastatic bone disease and multiple myeloma. Intravenous NBP administration often causes mild to severe acute-phase responses
(APRs) that may require intervention with analgesics and antipyretics and lead to treatment noncompliance and nonadherence. We here
undertook a phase IV safety trial in patients with osteoporosis to investigate the APR of otherwise healthy individuals to first-time
intravenous treatment with the NBP zoledronate. This study provides unique insight into sterile acute inflammatory responses in vivo, in
the absence of confounding factors such as infection or cancer. Our data show that both peripheral gd T cells and monocytes become
rapidly activated after treatment with zoledronate, which ultimately determines the clinical severity of the APR. Our study highlights a
key role for IFN-g in the zoledronate-induced APR and identifies pretreatment levels of monocytes and central/memory Vg9/Vd2 T cells
as well as their responsiveness to zoledronate in vitro as predictive risk factors for the occurrence of subclinical and clinical symptoms.
These findings have diagnostic and prognostic implications for patients with and without malignancy and are relevant for Vg9/Vd2 T-
cell–based immunotherapy approaches.  2013 American Society for Bone and Mineral Research.
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Introduction
There is increasing evidence that gd T cells play a key role inorchestrating and regulating immune responses in humans
and in animal models.(1) Our own recent findings demonstrate
that a rapid crosstalk of human gd T cells and monocytes drives
acute inflammatory responses, which may contribute to
pathogen clearance and protective immunity but may also lead
to tissue damage and poor clinical outcome.(2,3) For reasons
not yet understood, human gd T cells differ fundamentally
from those found in nonprimate species, and hence no small
animal model replicates the complex interactions between gd T
cells and other immune and nonimmune cells in the human
body.(4,5)
Nitrogen-containing bisphosphonates, or aminobisphospho-
nates (NBPs), are effective drugs against excessive bone
resorption in osteoporosis, Paget’s disease, metastatic bone
disease, and multiple myeloma. Despite their overall safety, NBP
therapy is frequently associated with mild to severe inflamma-
tory events, which may require intervention with analgesics and
antipyretics and lead to treatment noncompliance and non-
adherence.(6,7) Treatment with intravenous NBPs such as
pamidronate (Aredia; Novartis, Basel, Switzerland) and zoledro-
nate (Aclasta/Zometa; Novartis) may cause systemic acute-phase
responses (APRs) characterized by fever, pain, nausea, and
fatigue in up to 50% of all patients within 48 hours after
administration. These flu-like symptoms are typically transient,
resolve spontaneously, and are accompanied by decreased
lymphocyte counts and elevated levels of the pro-inflammatory
cytokines IL-6, IFN-g, and TNF-a.(8–11) The APR upon intravenous
treatment with NBPs is most severe in first-time treated patients,
whereas subsequent further administration induces no APR
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symptoms at all or an APR with much milder outcome than at
first exposure. For instance, in the HORIZON trial, net APR rates
were 30%, 7%, and 3% after zoledronate (ZOL) infusions 1 to 3,
respectively.(11,12) The immunological basis for this ‘‘tolerance’’ to
repeated treatment with NBPs is not known.
Kunzmann and colleagues were the first to ascribe a role for gd
T cells in the NBP-induced APR.(13) Subsequent cell culture–
based studies have elegantly demonstrated that NBPs are potent
stimulators of Vg9/Vd2þ gd T cells in vitro.(14–18) To act on
Vg9/Vd2 T cells, NBPs depend on uptake bymonocytes and other
endocytically active cell types, in which they inhibit farnesyl
pyrophosphate synthase (FPPS), a key enzyme in the biosynthe-
sis of sterols, ubiquinones, and other isoprenoids via the
mevalonate pathway. Preferential uptake by osteoclasts and
subsequent inhibition of FPPS is the prime mechanism of action
in the NBP-mediated prevention of bone resorption. However,
FPPS inhibition in osteoclasts, monocytes, and other cells also
leads to intracellular accumulation of upstream metabolites
including dimethylallyl pyrophosphate (DMAPP), isopentenyl
pyrophosphate (IPP), and an ATP conjugate of IPP (ApppI), which
may function as ‘‘danger’’ signals and be sensed by Vg9/Vd2 T
cells via a largely unknown mechanism.(19)
Despite the wealth of data from in vitro experiments, there has
been a paucity of studies addressing the cellular events in vivo in
NBP-treated patients. We here wished to study the physiological
consequences of the human gd T-cell interaction with mono-
cytes in vivo and provide unique insight into purely gd T cell–
mediated responses in the absence of confounding factors, by
investigating the immune response of otherwise healthy
individuals with osteoporosis to first-time administration of
intravenous ZOL. During the revision process of the present
study, Kalyan and colleagues reported the presence of
circulating monocytes with increased forward scatter in ZOL-
treated osteoporosis patients, yet did not characterize these cells
further nor give any indication as to the time frame of this
response.(20) Our own findings show that both gd T cells and
monocytes become rapidly activated after treatment with ZOL,
thus providing proof-of-concept for the crosstalk of both cell
types in vivo. Moreover, our study highlights a key role for IFN-g
in the NBP-induced APR and identifies pretreatment levels of
monocytes and Vg9/Vd2 T cells as well as the proportion of
central/memory TCM cells within the Vg9/Vd2 T-cell population
and their in vitro responsiveness to ZOL as predictive risk factors.
Materials and Methods
Patients
This study was approved by the South East Wales Local Ethics
Committee under reference number 10/WSE04/52, EudraCT
number 2009-017369-47, and conducted according to the
principles expressed in the Declaration of Helsinki and under
local ethical guidelines. All patients provided written informed
consent. The study cohort comprised 19 healthy nonsmoking
adult females with postmenopausal osteoporosis and a bone
density T-score of2.5 or worse at either total spine, total hip, or
neck of femur when measured by dual-energy X-ray absorpti-
ometry (DXA). The mean age was 68 years (range 57 to 79 years).
All study participants were NBP naı¨ve and attended outpatient
appointments at Cardiff Royal Infirmary for first-time infusion of
5mg ZOL (Aclasta). Inclusion criteria included no contra-
indications to treatment with intravenous NBPs; normal
creatinine clearance levels of >35mL/min; and normal vitamin
D levels of 30 to 100mg/L. Exclusion criteria included a body
temperature >38.58C at first visit; participation in another
therapeutic trial within 20 days of consent; history of illness that
might compromise participation such as drug or alcohol abuse;
hypocalcaemia (<2.2mmol/L corrected); and current use of oral
steroids or other immunosuppressive agents. Vital signs such as
resting pulse, resting blood pressure, and oral temperature and
APR symptoms were recorded before treatment (day 0) and on
days 1, 3, and 9 post infusion; cumulative APR scores (0 to 4)
comprised one or several of the following symptoms for at least
24 hours after treatment: fatigue, muscle pain, headache, and/or
joint pain. Blood parameters recorded included white blood cell
(WBC) counts, erythrocyte sedimentation rates (ESR), and plasma
levels of C-reactive protein (CRP) as markers of inflammation.
From all patients, 15mL of blood were drawn on each visit;
PBMCs were isolated using Lymphoprep (Axis-Shield, Dundee,
United Kingdom) and used directly for multicolor flow
cytometric analyses or stored in liquid nitrogen for later
stimulation assays.
Flow cytometry
Freshly isolated PBMCs were stained using monoclonal antibodies
against CD3 (SK7 and UCHT1), CD4 (SK3), CD8 (HIT8a), CD25
(M-A251), CD27 (M-T271), CD56 (B159), CD69 (FN50), and HLA-DR
(L243) from BD Biosciences, Oxford, United Kingdom; Vg9
(Immu360) and CD40 (MAB89) from Beckman Coulter, High
Wycombe, United Kingdom; NKG2D (1D11), CD14 (61D3), CD19
(SJ25C1), CD45RA (HI100), and CD80 (2D10.4) from eBioscience,
Hatfield, United Kingdom, together with appropriate isotype
controls. Cells were acquired on an eight-color FACSCanto II (BD
Biosciences) and analyzed with FloJo 7.6 (TreeStar, Ashland, OR,
USA). Leukocyte populations were identified based on their
appearance in side scatter and forward scatter area/height,
exclusion of live/dead staining (fixable Aqua; Invitrogen, Paisley,
United Kingdom), and surface staining: CD3CD56þ NK cells,
CD3CD14þ monocytes, CD3CD19þ B cells, and CD3þ T cells. T-
cell subsets were identified as CD3þCD4þCD8Vg9 helper T cells,
CD3þCD4CD8þVg9 cytotoxic T cells, CD3þCD56þVg9 NKT
cells, and CD3þVg9þ gd T cells.
Plasma analysis
Plasma samples were collected before PBMC separation and
stored at 808C. At the end of the study, all samples were
analyzed together on a SECTOR Imager 600 (Meso Scale
Discovery, Rockville, MD, USA) for IL-1b, IL-2, IL-6, IL-10, IL-
12p70, CXCL8, GM-CSF, IFN-g, and TNF-a (Human Pro-Inflam-
matory 9-Plex Assay Ultra-Sensitive Kit; Meso Scale Discovery). In
addition, CXCL10 and IL-17 were measured on a Dynex MRX II
reader, using conventional ELISA kits (R&D Systems, Abingdon,
United Kingdom).
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Cell culture
The medium used was RPMI-1640 with 2mM L-glutamine, 1%
non-essential amino acids, 50mg/mL penicillin/streptomycin,
and 10% fetal calf serum (Invitrogen). Frozen PBMC samples
were defrosted and cultured for 24 hours in medium or with
10mM ZOL (Zometa). Activation of Vg9/Vd2 T cells was analyzed
by flow cytometry using antibodies against CD3, Vg9, and CD69;
levels of IFN-g were measured on a Dynex MRX II reader, using
conventional ELISA kits (R&D Systems).
Statistical analysis
Differences between groups were analyzed using paired
Student’s t tests for normally distributed data or Wilcoxon
signed-rank matched pairs for nonparametric data using
GraphPad Prism 4.03 software. Advanced statistical analyses
were performed using SPSS 18.0. Differences between IFN-g
levels in groups with pretreatment frequencies of Vg9/Vd2 T cells
above or below the mean were analyzed using independent t
tests. Pearson’s correlations were used to assess any relation-
ships between variables; nonparametric variables not passing
the Shapiro-Wilk test were log-transformed as done for plasma
levels of IFN-g and TNF-a on day 1 and all IL-6 levels. Predictive
biomarkers were assessed using linear regression; statistically
significant (p< 0.05) variables from univariate analyses were
included in multiple regression analyses based on backward
selection. All statistical tests were two-tailed. Box-and-whisker
plots depict minimum, 25th percentile, median, 75th percentile,
and maximum values; arrows in Fig. 5 and Supplemental Figs. S1
and S2 depict significant correlations as assessed by Pearson’s
correlations and/or regression analyses as specified in the figure
legends. Asterisks indicate statistically significant differences to
pretreatment values as indicated in the table and the figures:
p< 0.05; p< 0.01; p< 0.001.
Results
First-time intravenous administration of ZOL causes APRs
in osteoporosis patients
Upon first-time intravenous treatment with ZOL, the majority of
patients experienced at least one APR symptom on day 1 (12/19)
and day 3 (15/19) after treatment, two-thirds of which
experienced at least two APR symptoms on day 1 (7/19) and
day 3 (10/19). Nine days after treatment, 7/19 patients still had an
APR score of 1. In line with the occurrence of APR symptoms,
oral temperatures and pulse rates of patients were elevated on
day 1 (Fig. 1). These changes were accompanied by a temporary
drop in WBC (p< 0.05) and a concomitant rise in ESR (p< 0.01)
on day 3 compared with baseline (not shown). Plasma levels of
CRP were elevated on days 1 and 3 but returned to baseline by
day 9 in most patients. Of note, all patients (19/19) showed
considerable increases in CRP levels by day 3, and increases in
CRP levels from baseline to days 1 and 3 correlated well with
cumulative APR scores on days 1 and 3 (Table 1). These findings
indicate not only that plasma CRP accurately reflected the
severity of the APR but also that all patients showed an objective
response to ZOL, albeit in many cases subclinically.
ZOL treatment induces systemic activation of gd T cells
To investigate the immunological basis of the APRs in our patient
cohort and to be able to identify biomarkers that may correlate
with, or even predict, the increase in CRP levels or the extent of
the clinical symptoms experienced, we measured a comprehen-
sive range of humoral and cellular immune parameters of
possible relevance in the APR. On the cellular level, we detected a
temporary drop in peripheral Vg9/Vd2 T cells (measured as
proportion of all circulating T cells) from 2.9 0.8% (mean
 SEM) down to 2.1 0.7% on day 3 (p< 0.05); these frequencies
returned to baseline levels by day 9 (Fig. 2A). In contrast,
proportions of CD4þ and CD8þ T cells were not affected (data
not shown). This transient30% decrease in Vg9/Vd2 T cells was
similar to the findings by Thompson and colleagues(18) in ZOL-
treated osteoporosis patients and confirms the specificity of ZOL
for Vg9/Vd2 T cells. Direct evidence for activation of Vg9/Vd2 T
cells was obtained by measuring surface expression of CD25,
CD69, HLA-DR, and NKG2D. Although CD25 levels remained
low throughout the study period, CD69, HLA-DR, and NKG2D
showed a significant upregulation on Vg9/Vd2 T cells
after treatment (Fig. 2B). Moreover, the distribution of
Vg9/Vd2 T-cell memory subsets changed significantly in that
the proportion of CD27þCD45RA central memory (TCM) cells
dropped, whereas CD27CD45RA effector/memory (TEM) cells
and CD27CD45RAþ terminally differentiated effector/memory
(TEMRA) cells increased after treatment (Fig. 2C). These changes in
the distribution of memory subsets were detectable for at least
9 days after treatment and indicated a longer-lasting systemic
effect of ZOL on the Vg9/Vd2 T-cell compartment beyond the
initial APR.
Fig. 1. Acute-phase response to intravenous ZOL in female osteoporosis
patients. Cumulative APR scores, CRP plasma levels, resting body tem-
peratures, and pulse rates immediately before and 1, 3, and 9 days after
intravenous ZOL administration. Differences were assessed using Stu-
dent’s t tests.
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ZOL treatment induces systemic activation of monocytes
Vg9/Vd2 T cells only respond to NBPs after uptake by monocytes
or other endocytically active cells.(17,19,21) Because Vg9/Vd2 T
cells stimulate monocyte survival and activation in vitro,(2,4) we
next examined the effects of ZOL administration on the
circulating monocyte population in vivo. Of note, we detected
a pronounced increase in the proportion of monocytes among
total PBMCs on day 1 (Fig. 3). However, it is not clear whether this
constituted a specific expansion of monocytes, as we detected a
similar increase in B cells and a parallel drop in T cells (data not
shown). This notwithstanding, there was a significant increase in
the surface expression of CD14, CD40, CD80, and HLA-DR at 1 to
3 days after treatment, indicative of a considerable but transient
activation of monocytes in vivo (Fig. 3) and evoking our earlier
demonstration of an intimate crosstalk between gd T cells and
monocytes in vitro.(2)
The ZOL-induced APR is characterized by elevated
plasma cytokine levels
We next measured a range of soluble mediators in patient
plasma, especially those that are associated with Vg9/Vd2 T-cell
and/ormonocyte responses. Among these, a sharp peak on day 1
was observed for IFN-g, with an average increase of 50-fold
over baseline (Fig. 4). Less pronounced but nevertheless
significant changes on day 1 were also detected for TNF-a
and IL-6, in accordance with earlier studies.(8,18,22) In addition,
changes were seen for IL-2, IL-10, and GM-CSF (Fig. 4) as well as
CXCL10 (data not shown). To our knowledge, the latter four
factors have not been implicated in the APR to NBPs before. In
contrast to these effects, plasma levels of IL-1b, IL-12p70, and
CXCL8 (Fig. 4) as well as IL-17 (data not shown) did not change
upon treatment with ZOL. These findings suggest that the APR to
ZOL, evidenced by the occurrence of clinical symptoms and
elevated CRP levels peaking at day 3, is preceded by a rapid and
transient production of a distinct set of inflammatory mediators
on day 1. Many of these factors were previously shown to play a
role in the crosstalk between activated Vg9/Vd2 T cells and
monocytes (IFN-g, TNF-a, GM-CSF, IL-6, CXCL10).(2)
IFN-g takes center stage in the APR to ZOL
In an attempt to delineate the molecular and cellular events after
systemic ZOL administration leading to the development of APR
symptoms, we performed a detailed statistical analysis of a large
range of humoral and cellular parameters, including the
proportions of monocytes, B cells, NK cells, Vg9/Vd2 T cells,
CD4 and CD8 T cells, and their expression of markers associated
with activated cells (CD25, CD69, NKG2D), antigen-presenting
Table 1. Correlations of CRP Values With APR Scores and
Immune Biomarkers
CRP increase
Parameter Day 1 Day 3
APR Day 1 0.510 0.690
Day 3 0.532 0.806
IFN-g Day 1 0.654 0.508
Day 3 0.452 0.245
IL-6 Day 1 0.595 –0.135
Day 3 –0.471 –0.154
% Vg9þ Day 0 0.637 0.325
Day 1 0.588 0.706
Day 3 0.400 0.464
Day 9 0.632 0.365
Note: CRP increases above baseline were calculated by subtracting
day 0 values. APR scores were expressed as cumulative symptoms on
day 1 (score 0 to 4) or days 1 and 3 (score 0 to 8). Biomarkers analyzed
before treatment (day 0) and on days 1, 3, and 9 after ZOL administration
included plasma levels of IFN-g and IL-6 (in pg/mL), and the frequency of
Vg9þ cells within the peripheral T-cell population. Values shown are
Pearson’s coefficients (r). Numbers in italics indicate nonsignificant
correlations.
p< 0.05.
p< 0.01.
Fig. 2. Activation of peripheral gd T cells after ZOL treatment. Proportion of Vg9þ T cells as percentage of all circulating CD3þ T cells (A); their surface
expression of CD25, CD69, HLA-DR, and NKG2D (B); and the relative proportion of CD27þCD45RAþ naive cells, CD27þCD45RA TCM cells,
CD27CD45RA TEM cells, and CD27
CD45RAþ TEMRA cells amongst circulating Vg9
þCD3þ T cells (C). Differences were assessed using Student’s t-tests.
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cells (CD40, CD80, HLA-DR), and/or memory cells (CD27,
CD45RA). Amongst these parameters, we identified a positive
correlation between IFN-g levels on either day 1 or day 3 and the
expression of CD69 on Vg9/Vd2 T cells on day 1 or day 3
(Supplemental Fig. S1A–D). CD69 expression on Vg9/Vd2 T cells
on day 3 also correlated moderately with plasma TNF-a levels on
day 3 (Supplemental Fig. S1D). Moreover, pretreatment
frequencies of Vg9/Vd2 T cells ultimately determined IFN-g
levels on day 1 (Supplemental Fig. S1A), and pretreatment
proportions of TCM cells within the Vg9/Vd2 T-cell population
accurately predicted the levels of IFN-g (Supplemental Fig. S1A)
as well as TNF-a (Supplemental Fig. S1E) detected on day 1. No
further post-treatment correlations were found between other
cellular parameters and plasma cytokine/chemokine levels,
except for a correlation between IFN-g levels on day 1 and
activation on NK cells on day 1 (Pearson’s coefficient, r¼ 0.640)
or day 3 (r¼ 0.766), measured as CD69 expression on CD56þ
CD3 cells (not shown). Taken together, these findings are
consistent with the view that activated Vg9/Vd2 T cells
are the prime source of the elevated levels of IFN-g in the
circulation, and that activated Vg9/Vd2 T cells may also induce
IFN-g production by other cell types such as NK cells.(23) A
proposed model incorporating the described correlations is
shown in Fig. 5. Of note, the depicted associations do not
represent the result of a comprehensive path analysis or causal
modeling but are derived from nonindependent regression
models (individual Pearson’s correlations and separate multivar-
iate analyses by backward selection as summarized in Table 1
and Supplemental Figs. S1 and S2) and should thus be
interpreted with caution because of the potential inclusion of
type I errors.
The occurrence of a specific monocyte-gd T-cell crosstalk in
ZOL-treated patients was supported by the demonstration that
pretreatment frequencies of monocytes in PBMCs but no other
pretreatment parameters correlated directly with the activation
levels of Vg9/Vd2 T cells on day 1, day 3, and day 9, expressed as
proportion of CD69þ cells (Supplemental Fig. S1F). Vice versa,
there was a modest correlation between the frequency of Vg9/
Vd2 T cells on day 1 and the activation status of monocytes on
day 1 (Pearson’s coefficient, r¼ 0.495) and day 3 (r¼ 0.557),
expressed as CD40 surface levels (not shown).
Of all humoral parameters measured, day 1 levels of IFN-g (and
IL-6) correlated with increased CRP levels on day 1 (Table 1)
(Supplemental Fig. S2A, B). Using linear regression, only IFN-g
levels on day 1 were predictive of total APR symptoms
(Supplemental Fig. S2A). No further correlations were found
between other plasma cytokines/chemokines and CRP levels or
APR symptoms. Taken together, these data emphasize a crucial
and previously underestimated role for IFN-g in the development
of a ZOL-induced APR. Of note, CRP levels also correlated
with pre- and post-treatment frequencies of Vg9/Vd2 T cells,
indicating that the extent of the APR upon ZOL administration is
influenced by the number of ZOL-responsive Vg9/Vd2 T cells
(Table 1). In accordance with previous findings,(24)) high Vg9/Vd2
T-cell frequencies were indeed associated with an increased risk
of APRs. Patients with pretreatment Vg9/Vd2 T-cell percentages
greater than the median of 3% had significantly higher levels of
IFN-g on day 1, with a mean difference of 127 pg/mL (confidence
interval 31 to 223 pg/mL; p< 0.05).
Fig. 3. Activation of peripheral monocytes after ZOL treatment. Propor-
tion of CD14þ monocytes as percentage of all PBMCs as well as surface
expression of CD14 (geometric mean fluorescence intensity [MFI]) and
CD40, CD80, and HLA-DR on circulating CD14þ monocytes. Differences
were assessed using Wilcoxon’s signed-rank tests for CD40 levels on
day 3 and Student’s t tests for all other parameters.
Fig. 4. Increased plasma cytokines and chemokines after ZOL treatment.
Plasma levels of the markers indicated as determined by multiplex ELISA.
Differences were assessed using Wilcoxon’s signed-rank tests for IL-1b,
IL-6, IL-10, and IL-12 levels and Student’s t tests for all other soluble
mediators.
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The in vitro responsiveness of pretreatment PBMCs
to ZOL predicts the APR in patients receiving
intravenous ZOL
Having established the crucial role of Vg9/Vd2 T cells, monocytes,
and IFN-g in the APR to ZOL, we finally tested whether the
response of pretreatment PBMCs to ZOL in vitro could predict
the APR in vivo. Activation markers determined included
the expression of CD69 on Vg9/Vd2 T cells and levels of
IFN-g in the culture supernatants after overnight stimulation with
ZOL. Statistical analyses demonstrated that the in vitro
responsiveness of PBMCs before treatment indeed predicted
the development of clinical symptoms and the levels of certain
blood biomarkers. As such, CD69 expression on Vg9/Vd2 T cells
after ZOL stimulation in vitro correlated with the IFN-g
concentrations in the culture supernatant of ZOL-stimulated
PBMCs as well as with plasma levels of IFN-g on day 1 in treated
patients (Supplemental Fig. S2C). Moreover, the IFN-g production
by ZOL-stimulated PBMCs correlated with plasma levels of IL-6
and CRP on day 1 as well as with cumulative APR scores by
day 3. These associations between in vitro and in vivo
parameters remained significant in multiple regression analyses
(Supplemental Fig. S2D) and are summarized in the proposed
model depicted in Fig. 5. Taken together, our findings
demonstrate that a simple screening test to help identify
individuals at risk of severe side effects upon intravenous NBP
treatment may be feasible.
Discussion
The present phase IV safety trial is themost comprehensive study
so far on the cellular immune response after intravenous NBP
administration and provides evidence that both Vg9/Vd2 T cells
and monocytes are involved in mediating the APR in vivo.
Moreover, our study identifies a key role for IFN-g in the NBP-
induced APR, which may be of diagnostic and prognostic value
and have implications for patient management. Given the
proven efficacy of NBPs to reduce the risk of fractures that
are associated with high mortality, a simple test predicting the
likelihood of a severe APR would allow the attending clinician to
tailor medication to the individual and improve adherence to
intravenous NBPs.
Our findings identify pretreatment frequencies of peripheral
monocytes and Vg9/Vd2 T cells as well as the proportion of
CD27þCD45RA TCM cells within the Vg9/Vd2 T-cell population
and their responsiveness to ZOL in vitro as important predictors
of the extent of pro-inflammatory cytokine production 24 hours
after treatment. Incidentally, the cut-off value of >3% Vg9/Vd2 T
cells identified by us above which patients showed considerably
elevated IFN-g levels at day 1 is in remarkable agreement with
the failure of Rossini and colleagues to observe an APR in ZOL-
treated osteoporosis patients who had pretreatment frequencies
below 3% gd T cells.(24) These observations imply that the age
and sex bias in peripheral Vg9/Vd2 T cells, which are higher in
younger individuals and in women, is an important determinant
of the APR incidence in different patient groups.(24,25)
Our study also shows that ZOL administration caused a
significant (albeit transient) drop in peripheral Vg9/Vd2 T cells
and a longer-lasting reduction in the percentage of TCM cells
among them. Earlier studies reported a similar drop in circulating
Vg9/Vd2 T cells in osteoporosis patients after receiving a single
dose of ZOL(18) and a loss of TCM cells in cancer patients treated
repeatedly with ZOL.(26–28) As the loss of TCM cells occurring after
a single administration of ZOL may last for at least a year,(29) the
qualitative and quantitative long-term effects of NBPs on the
Vg9/Vd2 T-cell compartment appear to be the underlying basis
for the general absence of adverse events in patients receiving
repeat treatments.(11,24) However, this correlation between the
numbers of TCM cells in the circulation, the plasma levels of IFN-g
reached shortly after ZOL treatment, and the occurrence of APR
symptoms is seemingly at odds with the present paradigm in
Vg9/Vd2 T-cell biology.(30) TCM cells are generally perceived as
cells with high proliferative capacity but only modest cytokine
production, as opposed to TEM and TEMRA cells, which proliferate
poorly but produce copious amounts of cytokines upon
restimulation. Our findings suggest that, in fact, activated TCM
cells are the major source of the IFN-g detected in the circulation
after ZOL treatment, emphasizing the importance of in vivo
studies in patients.
It is known from cell culture experiments that NBP-driven Vg9/
Vd2 T-cell responses are sensitive to statins.(16) By inhibiting 3-
hydroxy-3-methyl-glutaryl-CoA (HMG-CoA) reductase, the rate-
limiting enzyme of the mevalonate pathway, statins lower the
synthesis of all downstream isoprenoids including cholesterol,
which is exploited in the clinic to prevent cardiovascular
diseases. Through the same mechanism, statins also counteract
Fig. 5. Proposed relationships of pre- and post-treatment immune
parameters, in vitro biomarkers, and clinical response. Biomarkers ana-
lyzed before treatment (day 0) and on days 1, 3, and 9 after ZOL
administration included plasma levels of IFN-g, TNF-a, IL-6, and CRP;
the proportion of CD14þ monocytes among PBMCs; the frequency of
Vg9þ cells within the peripheral T-cell population; and the percentage of
CD27þCD45RA TCM cells and CD69
þ cells within the Vg9þ T-cell
population. In vitro parameters determined included concentrations of
IFN-g secreted into the culture supernatant and the percentage of CD69þ
Vg9/Vd2 T cells after overnight stimulation of pretreatment PBMCs with
ZOL. APR scores were calculated as cumulative APR symptoms on days 1
and 3 after ZOL administration.
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the NBP-induced intracellular accumulation of IPP, DMAPP, and
ApppI, and thus inhibit the activation of Vg9/Vd2 T cells in
vitro.(19) However, studies investigating the efficacy of statins in
preventing the APR to intravenous NBPs have failed to
demonstrate a clinical benefit,(11,18,22,31,32) most likely because
the plasma concentrations required for effective inhibition of
IPP/DMAPP/ApppI accumulation may not be reached pharma-
cologically. Our present findings suggest that interference with
key players in the NBP-dependent gd T cell-monocyte crosstalk
such as IFN-g might be an alternative therapeutic approach to
manipulate the APR in patients at risk of severe reactions.
The present study has implications beyond the APR in
osteoporosis patients. Recently, a transient drop in Vg9/Vd2 T-
cell levels was interpreted as extravasation of activated cells into
peripheral tissues,(18) evoking similar findings in primate studies
upon intravenous treatment with Vg9/Vd2 T-cell agonists.(33,34) It
is interesting to note that in primates activated Vg9/Vd2 T cells
accumulate in the lung where they may confer some degree of
protection against subsequent infection, which may be mirrored
by reports showing that intravenous ZOL treatment has a largely
unexplained beneficial effect in reducing pneumonia-related
mortality.(35)
Our findings also have implications for current attempts to
utilize NBP-based treatment regimes for targeted therapy of
cancer patients. Large cohort studies have shown that ZOL has
beneficial effects beyond improving bone health and may
prolong disease-free and/or overall survival in patients with
breast cancer(36) and multiple myeloma.(37) The underlying
reason for these direct antitumor properties is not clear but may
involve gd T-cell–mediated effects. ZOL and other NBPs are,
therefore, increasingly moving into the focus of novel
immunotherapeutic approaches, especially in combination
with low-dose IL-2 to boost the expansion and cytotoxicity of
Vg9/Vd2 T cells.(27,28,38,39) Previous studies identified possible
‘‘responders’’ and ‘‘nonresponders’’ based on the proliferative
capacity of a patient’s Vg9/Vd2 T cells to NBP stimulation in
vitro.(14,40,41) However, it remains to be investigated whether
the severity of the APR or levels of early immune biomarkers
such as those described here correlate with long-term clinical
outcomes after administration of NBPs with or without IL-2.
Taken together, our data are consistent with a model in which
intravenously administered ZOL is taken up by monocytes,
which thereby acquire the ability to ‘‘present’’ isoprenoid
metabolites or related structures to Vg9/Vd2 T cells.(17,19)
Through mutual crosstalk, both monocytes and Vg9/Vd2 T cells
undergo a series of activation and differentiation steps that
ultimately determine the severity of the APR and replicate similar
events taking place in acute infection.(2,4) Although the effects on
circulating monocytes appear to be only transient (be it because
of rapid inactivation, extravasation and/or replenishment from
the bone marrow), the Vg9/Vd2 T-cell pool shows longer-term
changes in that TCM cells disappear and TEM cells and TEMRA cells
become more prominent. Our findings imply that the gradual
loss of TCM cells and their inability to produce IFN-g is a
major determinant of the reduced risk of experiencing APR
symptoms in patients repeatedly treated with NBPs. Future
studies will reveal whether the immediate response to first-
time NBPs determines clinical outcome in patients with and
without malignancy and whether it has diagnostic and/or
prognostic value for Vg9/Vd2 T-cell–based immunotherapy
approaches.
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